Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

IN8BIO, INC. Director's Dealing 2025

May 8, 2025

35200_dirs_2025-05-07_f7417388-4824-4294-9b19-b352c4554a86.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: IN8BIO, INC. (INAB)
CIK: 0001740279
Period of Report: 2025-04-27

Reporting Person: Graff Jeremy R. (N/A)

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2025-04-27 Series B Warrants (right to buy) $1.50 D 2049 Disposed 2028-12-13 Common Stock (2049) Direct
2025-04-27 Series B Warrants (right to buy) $0.45 A 2049 Acquired 2028-12-13 Common Stock (2049) Direct

Footnotes

F1: The reported transaction involved an amendment of an outstanding warrant, resulting in the deemed cancellation of the "old" warrant and the grant of a "replacement" warrant. The warrant was originally granted on December 13, 2023 with an exercise price of $1.50 per share. The exercise price was reduced to $0.45 per share.

F2: Fully vested and exercisable.

F3: The reported securities are included within 2,049 units purchased by the Reporting Person on December 13, 2023 for $1.22 per unit. Each unit consists of one share of common stock, one Series A warrant and one Series B warrant, each warrant represents the right to purchase 2,049 shares of common stock.